Unit of Dermatology and Dermatosurgery, CDI Hospital, Milan, Italy.
Biological Communications Limited, London, United Kingdom.
Dermatol Surg. 2019 Dec;45(12):1598-1604. doi: 10.1097/DSS.0000000000001932.
VYC-12 is a novel hyaluronic acid-based dermal filler designed to treat fine lines and improve skin quality. A specialist digital camera and proprietary Digital Analysis of the Cutaneous Surface (DACS) software have previously been used to objectively measure changes in skin features.
To assess the effect of facial treatment with VYC-12 on skin texture using the specialist camera.
This was a prospective, open-label, 2-center study of 40 women aged 35 to 60 years treated with multiple, microdepot intradermal injections of VYC-12 (2 mL in the face; 1 mL in the neck if required). Eight patients (20.0%) required a touch-up at Day 45. Images were acquired using the specialist camera at baseline and 45 days and 6 months after treatment, and were analyzed by DACS. Clinical improvements were also assessed subjectively using the Global Aesthetic Improvement Scale (GAIS).
VYC-12 improved skin texture from baseline after 45 days (mean improvement: 25.9% ± 9.2%) and 6 months (mean improvement: 30.7% ± 18.2%). Improvements were also evident using the GAIS. There were no major adverse events.
VYC-12 improves skin quality, as measured using an objective, fast, and reproducible measuring tool. VYC-12 represents a valuable addition to the treatment armamentarium.
VYC-12 是一种新型的透明质酸真皮填充剂，旨在治疗细纹并改善皮肤质量。以前曾使用专业相机和专有的皮肤表面数字分析 (DACS) 软件客观测量皮肤特征的变化。
使用专业相机评估 VYC-12 对面部皮肤纹理的影响。
这是一项前瞻性、开放标签、2 中心研究，共纳入 40 名年龄在 35 至 60 岁之间的女性，接受多次微注射 VYC-12（面部 2 毫升；颈部 1 毫升，如果需要）。8 名患者（20.0%）在第 45 天需要补针。治疗前、治疗后 45 天和 6 个月使用专业相机采集图像，并使用 DACS 进行分析。还使用全球美学改善量表（GAIS）进行主观评估。
VYC-12 在治疗后 45 天（平均改善：25.9% ± 9.2%）和 6 个月（平均改善：30.7% ± 18.2%）改善了皮肤纹理。GAIS 也显示出明显的改善。没有严重不良事件。
VYC-12 可改善皮肤质量，使用客观、快速和可重复的测量工具进行测量。VYC-12 是治疗手段的有价值的补充。
